The World Health Organization says it is unclear how these powerful medications would affect young children over the long term.
Recap by typeshit. Full story at Bloomberg.
The Form 483 cites microbial growth in a clean hood, reversed cleanroom air pressure and active ingredients marked for research use only. Check which pharmacy filled your vial.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
A retrospective look at 65 patients at Leicester's HIV service from 2024 to 2026 turned up an unexpected rate of HIV viral rebound among GLP-1 users.
Medical Xpress reports a small pilot study where people coming off GLP-1 treatment got structured support, with early signs it may help them keep weight off.
Loading…